Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.68
- Piotroski Score 3.00
- Grade Overweight
- Symbol (CDXS)
- Company Codexis, Inc.
- Price $3.93
- Changes Percentage (1.16%)
- Change $0.05
- Day Low $3.72
- Day High $4.15
- Year High $4.91
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $11.00
- High Stock Price Target $11.00
- Low Stock Price Target $11.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.94
- Trailing P/E Ratio -3.47
- Forward P/E Ratio -3.47
- P/E Growth -3.47
- Net Income $-76,240,000
Income Statement
Quarterly
Annual
Latest News of CDXS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Codexis Inc (CDXS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Focus ...
The company aims to focus on moving projects to revenue-generating development within their ECO Innovation Lab. They prioritize partnerships with major siRNA drug developers and emphasize quality over...
By Yahoo! Finance | 2 weeks ago -
Investors in Codexis (NASDAQ:CDXS) have unfortunately lost 88% over the last three years
Long-term shareholders of Codexis, Inc. have faced an 88% drop in share price over three years. With recent falls, it's essential to assess underlying fundamentals for potential returns. Despite reven...
By Yahoo! Finance | 4 months ago
